<span item_type="fundamental" item_id="c5a5adb2425bcc617b45fea11478632c" counter_id="ST/US/IXHL" env="prod"></span><span item_type="announcement" item_id="566065486519407617" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 86 K.</p><p>EBIT: As of FY2025, the actual value is USD -23.42 M.</p><p></p><h3>Revenue from Customers</h3><p>Revenue from customers increased by 617% from $12,000 in the fiscal year ended June 30, 2024, to $86,000 in the fiscal year ended June 30, 2025, primarily due to the expansion of rehabilitation services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Operating Expenses</h3><h4>Research and Development (R&amp;D)</h4><p>R&amp;D expenses decreased by 17% from $12.9 million in the fiscal year ended June 30, 2024, to $10.7 million in the fiscal year ended June 30, 2025, primarily due to a pause in development activities for resource conservation reasons.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>General and Administrative</h4><p>General and administrative expenses decreased by 24% from $17.2 million in the fiscal year ended June 30, 2024, to $13.1 million in the fiscal year ended June 30, 2025. This decrease was mainly due to a reduction in share-based compensation expense and a decrease in cash paid related to trade and other payables.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Other Income (Expense)</h3><h4>Benefit from R&amp;D Tax Credit</h4><p>Benefit from R&amp;D tax credit decreased by 85% from $11.4 million in the fiscal year ended June 30, 2024, to $1.8 million in the fiscal year ended June 30, 2025, primarily due to multiple years of tax incentives being granted and successful lodgement of overseas findings on the Company’s lead assets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Foreign Exchange Losses</h4><p>Foreign exchange losses increased by 932% from $28,000 in the fiscal year ended June 30, 2024, to $289,000 in the fiscal year ended June 30, 2025, primarily due to unfavorable currency exchange rates during the period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Change in Fair Value of Convertible Rights</h4><p>The changes in the fair value of convertible rights amounted to $299,000 for the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Change in Fair Value of Warrant Liabilities</h4><p>The changes in the fair value of warrant liabilities amounted to $21.9 million for the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Loss on Extinguishment</h4><p>The total loss on extinguishment amounted to $1.5 million for the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>ELOC Commitment Fee</h4><p>The commitment fee expense incurred for the fiscal year ended June 30, 2025, was $1.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Currency Translation Adjustment Losses</h3><p>Currency translation adjustment, net of tax increased by 370% from a loss of $77,000 in the fiscal year ended June 30, 2024, to a gain of $208,000 in the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Net Loss</h3><p>Net loss increased by 154% from $18.5 million in the fiscal year ended June 30, 2024, to $46.7 million in the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Cash Flows</h3><h4>Operating Activities</h4><p>Net cash used in operating activities decreased by $3.3 million from $15.8 million in the fiscal year ended June 30, 2024, to $12.5 million in the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Investing Activities</h4><p>Net cash used in investing activities decreased by $0.3 million from $277,000 in the fiscal year ended June 30, 2024, to $8,000 in the fiscal year ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h4>Financing Activities</h4><p>Cash provided by financing activities increased by $21.4 million in the fiscal year ended June 30, 2025, compared to the fiscal year ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p><h3>Outlook / Guidance</h3><p>The Company plans for additional capital through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including collaborations with other companies or other strategic transactions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1873875/000121390025092837/ea0258594-10k_incannex.htm"></span></p>

Incannex Healthcare | 10-K: FY2025 Revenue: USD 86 K